Steward Financial Group’s Allogene Therapeutics ALLO Stock Holding History

Steward Financial Group’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7	Closed	–	–	706
2022 Q4	$0	Buy	+7	New	+$65	﹤0.01%	530

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Steward Financial Group's ALLO Position: Q1 2023 in Review

Steward Financial Group sold out of Allogene Therapeutics (ALLO) in Q1 2023, closing a stake of 7 shares.

Steward Financial Group first reported a position in ALLO in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 176 funds tracked by Wall St. Rank hold ALLO as of Q1 2023.

Steward Financial Group reported no remaining Allogene Therapeutics position as of Q1 2023 after selling out during the quarter.
Steward Financial Group sold 7 Allogene Therapeutics shares in Q1 2023.
Steward Financial Group first reported a position in Allogene Therapeutics in Q4 2022 and held it in 1 quarter.
Steward Financial Group's Allogene Therapeutics position peaked at $0 in Q4 2022.
176 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2023.

Based on Steward Financial Group's 13F filing for Q1 2023, filed 5 May 2023.